After yesterday’s enlightening conversation on novel ways to jumpstart the immune system including OX40, vaccines, and STING with a self-confessed radicalist aka cancer immunologist (Dr Bernard Fox), we now turn to a self-described optimist for an industry perspective on oncology R&D and Part 2 of our anti-OX40 mini-series:
- What ideas and challenges need to be considered in order to develop a new agent against a novel target, alone or in combination with another unapproved agent?
- We know that mouse models and biomarkers aren’t optimal yet, so how do those issues and other factors influence decision making and clinical trial design?
- It’s not so easy as many think – there are way more unknowns than knowns – so how do companies go about tackling them?
- What can we learn from the readouts?
To learn more, subscribers can login or you can click on the blue box below to purchase a subscription and read the OX40 mini-series, as well as our comprehensive AACR coverage…